Total
0
Shares
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham - The Market Herald
CEO, James Graham
Source: Finance News Network
  • Recce Pharmaceuticals (RCE) has completed its capital raise and successfully raised $27.95 million
  • All up, 21.5 million fully paid ordinary shares will now be issued to institutional, professional and sophisticated investors at $1.30 each
  • Due to the strong support received from investors, Executive Chairman Dr Graham Melrose has agreed to sell more than 1.57 million shares for $2.05 million
  • Recce will use the money to advance its antibiotics, complete phase one human clinical trials, and fund anticipated phase one and two topical studies
  • Shares are expected to be issued on or around September 30
  • Recce is down 3.67 per cent on the market and shares are trading for $1.58 each

Recce Pharmaceuticals (RCE) has completed its capital raise and successfully raised $27.95 million.

The antibiotic maker entered a trading halt on September 21 but did not disclose how much it would be raising.

All up, 21.5 million fully paid ordinary shares will now be issued to institutional, professional and sophisticated investors at $1.30 each.

This price represents a 20.5 per cent discount to the $1.64 closing price of RCE shares on September 18, and a 16 per cent discount to the 20-day volume-weighted average price of $1.55.

Due to the strong support received from investors, Executive Chairman Dr Graham Melrose has agreed to sell 1,576,923 shares for $2.05 million.

Recce will use the money to advance its RECCE 327, RECCE 435 and RECCE 529 antibiotics, complete phase I human clinical trials, and fund anticipated phase I and II topical studies.

"We greatly appreciate the support shown by both our existing investors and new institutional investors. Their financial support comes at a transformative time for Recce as we prepare to advance human clinical trials," CEO James Graham said.

Shares are expected to be issued on or around September 30.

Recce is down 3.67 per cent on the market and shares are trading for $1.58 each at 1:04 pm AEST.


Subscribe


RCE by the numbers
More From The Market Herald
EVE Investment (ASX:EVE) - Managing Director, Bill Fry - The Market Herald

" EVE Investments (ASX:EVE) increases revenue and cash balance in Q1 FY21

Wellness business EVE Investments (EVE) has announced a record start to FY21, increasing both its revenue and cash balance during the September quarter.
Holista Colltech (ASX:HCT) - Managing Director, Dr Rajen Manicka - The Market Herald

" Holista CollTech’s (ASX:HCT) Path-Away kills 99.9pc of COVID-19

The coronavirus rollercoaster continues for small-cap biotech company Holista CollTech (HCT) today, with its share price almost doubling on the company’s latest announcement.
Imagion Biosystems (ASX:IBX) appoints Geoff Hollis as CFO

" Imagion Biosystems (ASX:IBX) appoints Geoff Hollis as CFO

Imagion Biosystems (IBX) has appointed Geoff Hollis as its new Chief Financial Officer (CFO).
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson - The Market Herald

" Anteris Technologies (ASX:AVR) one step closer to biologic heart valve

Anteris Technologies (AVR) is continuing to make progress in the development of its DurAVR 3D single-piece aortic valve.